Biopharma AI
By
Chai Discovery Becomes Newest AI Unicorn Following $130 Million Series B Financing
Company valued at $1.3 billion as investors back AI-native drug discovery platform San Francisco, California Chai Discovery today…
PhaseV Reports Breakthrough Year in 2025, Marking Transition to Scaled AI Deployment in Clinical Development
Boston, Massachusetts PhaseV announced today that 2025 marked a defining year for the company, highlighted by record revenue…
Takeda Announces Positive Phase III Results for AI-Discovered Oral Psoriasis Therapy
Tokyo, Japan – December 19, 2025 – Takeda Pharmaceutical Company Limited today announced successful results from two Phase…
Cradle AI-powered protein engineering platform serving six of the top 25 global pharma leaders
AMSTERDAM and ZURICH, Dec. 16, 2025 — Cradle, an enterprise-grade AI software platform for protein engineering, today announced…
Which AI Biopharma Startups Truly Won in 2025—And How Did NVIDIA, Big Pharma Collaborations, and Deal Value Define Success?
Executive Perspective 2025 marked a decisive shift for AI biopharma startups—from experimental promise to measurable strategic impact. Success…
Is Nabla Bio Redefining AI-Driven Protein Engineering as Pharma Seeks Faster Paths to Biologics Innovation?
Executive Summary Nabla Bio is emerging as a next-generation AI biotech focused on computationally driven protein and antibody…
